Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 5Prostatic Neoplasms 4Glioma 4Lung Neoplasms 3Epstein-Barr Virus Infections 3Astrocytoma 3Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Cytomegalovirus Infections 2Breast Neoplasms 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Stomatitis 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1

Interventions

Matrix-M 2valomaciclovir 1Valacyclovir 1Rituximab 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Infectious Mononucleosis × Valacyclovir × Clear all
NCT00274404 2011-10-27

Controlled Trial of Valacyclovir in Infectious Mononucleosis

University of Minnesota

Phase 1/2 Completed
20 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡